Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)
详细信息 查看全文
- 作者：Minoru Fukuda ; Midori Shimada ; Takeshi Kitazaki ; Seiji Nagashima ; Kohji Hashiguchi ; Noriyuki Ebi ; Koichi Takayama ; Yoichi Nakanishi ; Hiroshi Semba ; Taishi Harada ; Takashi Seto ; Isamu Okamoto ; Yukito Ichinose and Kenji Sugio
- 刊名：Thoracic Cancer
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：8
- 期：1
- 页码：40-45
- 全文大小：122K
- ISSN：1759-7714
文摘
Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose (MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung cancer patients with the UGT1A1 *28 or UGT1A1 *6 polymorphism.